free survival (PFS) by 7.1 months in patients with advanced, progressive, welldifferentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P < .00001). This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs. In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best Abbreviations: AC, atypical carcinoid; AE, adverse event; CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; NET, neuroendocrine tumor; OS, overall survival; PFS, progression-free survival; PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analog; TC, typical carcinoid.
supportive care. This is a post hoc analysis of the lung subgroup with PFS, by central radiology review, as the primary endpoint; secondary endpoints included objective response rate and safety measures. Ninety of the 302 patients enrolled in the study had primary lung NET (everolimus, n = 63; placebo, n = 27). Median PFS (95% CI) by central review was 9.2 (6.8-10.9) months in the everolimus arm vs 3.6 (1.9-5.1) months in the placebo arm (hazard ratio, 0.50; 95% CI, 0.28-0.88). More patients who received everolimus (58%) experienced tumor shrinkage compared with placebo (13%). Most frequently reported (≥5% incidence) grade 3-4 drug-related adverse events (everolimus vs. placebo) included stomatitis (11% vs. 0%), hyperglycemia (10% vs. 0%), and any infections (8% vs. 0%). In patients with advanced, progressive, well-differentiated, non-functional lung NET, treatment with everolimus was associated with a median PFS improvement of 5.6 months, with a safety profile similar to that of the overall RADIANT-4 cohort. These results support the use of everolimus in patients with advanced, non-functional lung NET. The trial is registered with ClinicalTrials.gov (no. NCT01524783).
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| INTRODUCTION
Neuroendocrine tumors are a diverse group of malignancies arising from neuroendocrine cells throughout the body. 1 The majority (>90%) of NETs originating from the lungs are non-hormone secreting (i.e., non-functional). 2 Lung carcinoids (otherwise called lung NETs) represent 22%-27% of all NETs 3, 4 and approximately 1%-2% of all primary lung cancers. 5 The annual age-adjusted inci- cancers, respectively. 6 Approximately 4% of TC and 26% of AC develop distant metastases. 7 According to an analysis of the Surveillance, Epidemiology and End Results registry, the 5-year survival rate in patients with well-differentiated lung NETs with distant metastases is 27%. 1 Platinum and etoposide represent a relatively standard treatment in poorly differentiated lung neuroendocrine carcinoma, such as large-cell neuroendocrine carcinoma and small-cell lung cancer. 8, 9 By contrast, therapeutic approaches are more varied for well-differentiated lung NETs, with several different potentially active therapies being explored in this patient group, including SSAs, 10 PRRT, 11, 12 molecular targeted agents, [13] [14] [15] and some chemotherapeutics such as alkylating agents, oxaliplatin, and fluoropyrimidines. [16] [17] [18] However, substantial evidence regarding the efficacy of these agents as antiproliferative therapies is lacking. Therefore, no antitumor therapy has yet been approved for patients with lung NETs.
Everolimus, an oral selective inhibitor of mTOR, a key component that mediates cell growth, proliferation, and survival, has shown antitumor activity in patients with advanced NETs. [19] [20] [21] In the phase III RADIANT-4 study, comprising of patients with advanced, progressive, well-differentiated, non-functional lung or GI NET (n = 302), everolimus showed an improvement in median PFS of 7.1 months and a 52% reduction in the risk of disease progression or death (HR, 0.48; 95% CI, 0.35-0.67; P < .00001) compared with placebo. 22 The present analysis aimed to further explore the efficacy and safety of everolimus in the lung subgroup of the RADIANT-4 study cohort.
| MATERIALS AND METHODS

| Study design
RADIANT-4 was a prospective, double-blind, randomized, parallelgroup, placebo-controlled, multicenter phase III study in which everolimus 10 mg/d was compared with placebo, both with best supportive care, in patients with advanced, progressive, welldifferentiated (grade 1 or grade 2), non-functional lung or GI NET with no history of or active symptoms of carcinoid syndrome (NCT01524783). Details of the study design were published previously. 22 Of the 388 patients screened, 302 were randomized in a tions. An independent ethics committee or institutional review board at each participating center reviewed and approved the study and all protocol amendments. All patients provided written informed consent. An independent data monitoring committee provided ongoing oversight of safety and study conduct.
| Assessment
All patients who underwent randomization were assessed for efficacy by cross-sectional imaging with multiphasic computed tomogra- 
| Statistical analysis
This is an exploratory subgroup analysis of patients with lung NET as a primary site enrolled in the RADIANT-4 study. The full analysis set (all randomized patients) was used for all efficacy analyses. Sample size calculations were not undertaken for the cohort of patients described in this report and so this analysis was not powered to compare the treatment groups. Progression-free survival, by central radiology review, was analyzed using Kaplan-Meier methods. Hazard ratios and corresponding CIs were estimated using an unstratified Cox proportional hazards model. All patients who received on or more doses of study drug and who had one or more post-baseline safety assessments were included in the safety cohort.
3 | RESULTS
| Patient characteristics
Of the 302 patients in the RADIANT-4 study, 90 patients had advanced, progressive, well-differentiated, non-functional NET of lung origin and were included in this analysis; of them, 63 received everolimus and 27 received placebo. In the everolimus arm, one patient was not treated due to withdrawal of consent. Therefore, the safety cohort in the everolimus arm was comprised of 62 patients.
The majority of the patients were men (52.2%), Caucasian (85.6%), and characteristics by treatment arm are described in Table 1 .
Either tumor morphology or grade of malignancy was collected for the lung NET patient group (n = 90). Tumors were defined as "well" or "moderately" differentiated based on local pathology assessment. Among the patients in whom tumor morphology was reported (n = 38), the majority were reported to have well-differentiated NET (n = 32; 84.2%). Moderately differentiated NET was reported in 6 patients (15.8%). Considering the lack of consensus among pathologists on the precise definition, patients with moderately differentiated NETs were eligible for inclusion in this study provided that a poorly differentiated high-grade neuroendocrine carcinoma was ruled out, consistent with the exclusion criteria of the study protocol. Among the patients in whom tumor grade was reported (n = 51), majority (86.2%) had an intermediate grade NET.
In the patients in whom Ki-67 percentage was reported (n = 63), it varied from 0% to 60% (median, 8%). Three patients in the everolimus arm had a Ki-67 index >20% (30%, 50%, and 60%). The investigators confirmed the eligibility of these three patients based on well-differentiated tumor morphology as reviewed by the local pathologist. These dose adjustments were primarily attributable to AEs (69.4%).
| Treatment
In the placebo arm (n = 27), 8 patients (29.6%) had one or more adjustments (reduction or interruption) of dosage and 18.5% of dose adjustments were due to AEs.
| Efficacy
The median PFS, by central review, was 9.2 months (95% CI, 6.8-10.9) for patients receiving everolimus compared with 3.6 months (95% CI, 1.9-5.1) for those receiving placebo. Everolimus improved the median PFS by 5.6 months and was associated with a 50% reduction in the risk of disease progression or death (HR, 0.50; 95% CI, 0.28-0.88) ( Figure 1A ). By local investigator assessment (Figure 1B) , median PFS was 13.8 months (95% CI, 9.3-22.2) for patients receiving everolimus compared with 3.5 months (95% CI, 1.9-5.6) for those receiving placebo (HR, 0.23; 95% CI, 0.13-0.41). In addition, more patients who received everolimus (57.9%) experienced tumor shrinkage compared to those receiving placebo (13.0%).
Details of the overall response and tumor shrinkage are presented in (Table 2 ).
| Safety
The most common AEs in the lung NET subgroup, irrespective of the study drug relationship (≥20% incidence in either arm), were 14.8%), decreased appetite (24.2% vs. 11.1%), nausea (22.6% vs.
14.8%), and anemia (21.0% vs. 3.7%). The most frequent grade 3-4
AEs irrespective of the study drug relationship (≥5% incidence in either arm) were stomatitis (11.3% vs. 0.0%), hyperglycemia (9.7% vs. 0.0%), diarrhea (6.5% vs. 0.0%), hypophosphatemia (6.5% vs.
0.0%), dyspnea (4.8% vs. 7.4%), and hypertension (0.0% vs. 7.4%).
The most frequently reported (≥20% incidence in either arm) with pneumonitis had stable disease as their best response per central radiology review. The most frequent grade 3-4 drug-related AEs (≥5% incidence in either arm) were stomatitis, hyperglycemia, and infections (Table 3 ).
There were two on-treatment deaths in each arm. In the everolimus arm, one of the two deaths was considered to be related to the primary disease and/or to disease progression, and the other was
Probability of progression-free survival (%)
Everolimus Placebo was not available and patients for whom the best percentage change was contradicted by overall lesion = unknown were excluded from the analyses attributed to "cardiac failure", which was not suspected by the investigator to be related to the study medication. In the placebo arm, one death was considered to be related to the primary disease and/ or to disease progression and the other death was attributed to "dyspnea", which was suspected by the investigator to be related to the study medication. The AEs observed in this subgroup of patients with lung NET were similar to those reported in the overall RADI-ANT-4 patient group.
| DISCUSSION
There is a large unmet medical need for patients with advanced lung Overall lung subgroup (n = 90) 9.2 (6.8-10.9) 3.6 (1.9-5.1)
Prior chemotherapy (n = 38) 8.5 (5.6-11.7) 2.9 (1.8-3.7)
No prior chemotherapy (n = 52) 9.2 (6.0-NE) 3.7 (1.7-NE)
Prior SSA (n = 38) 9.5 (6.0-11.7) 3.7 (1.0-11.2)
No prior SSA (n = 52) 9.2 (5.6-11.0) 3.6 (1.9-5.6)
Prior radiotherapy a (n = 38) 9.2 (5.7-NE) 3.0 (1.9-5.1)
No prior radiotherapy (n = 52) 9.2 (6.0-9.9) 3.7 (1.7-NE)
Any prior therapy (n = 78) 9.2 (6.0-11.0) 3.4 (1.9-5.1)
No prior therapy (n = 12) 9.7 (0.9-NE) 3.6 (1.7-NE) CI, confidence interval; NE, not evaluable; SSA, somatostatin analog.
a Includes peptide receptor radionuclide therapy.
T A B L E 3 Drug-related adverse events in the lung subgroup of of patients with advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) treated with everolimus or placebo (≥10% incidence in either arm) mus. 22 The data from our analysis supports the preliminary evidence of efficacy that was observed when everolimus was added to octreotide in patients with functional lung NET. 19 The results from the three-arm, randomized phase II LUNA trial (n = 112), comparing pasireotide in combination with everolimus vs everolimus alone and pasireotide alone in patients with typical and atypical lung or thymic carcinoids further support the efficacy of everolimus in this setting. 27 The LUNA study achieved the preplanned statistical objective of a 9-month PFS rate >20% in all three arms. The observed 9-month PFS rates were 39.0%, 33.3%, and 58.5% with a median PFS of 8.5, 12.5, and 11.8 months in pasireotide alone, everolimus alone, and combination arms, respectively.
The preplanned first interim OS analysis (at data cut-off date of November 28, 2014) was carried out after a total of 70 deaths and indicated that everolimus may be associated with a reduction in the risk of death (HR, 0.64; 95% CI, 0.40-1.05; one-sided P = .037, whereas the boundary for statistical significance was .0002). 22 The results of a planned second interim analysis of OS (at data cut-off date of November 30, 2015), undertaken after a total of 101 deaths (53% of the total targeted 191 deaths for final OS analysis), continued to suggest a positive trend for survival benefit with everolimus, although statistical significance was not achieved. 28 Overall survival was immature at the interim analyses. Therefore, the OS in subgroups will be analyzed when the final OS analysis will be under- Everolimus toxicity was manageable with no new safety signals.
In patients with lung NET, drug-related pneumonitis is of special interest; however, all patients in this lung subgroup who had grade 1-3 drug-related non-infectious pneumonitis were effectively managed with dose modifications, without requiring treatment discontinuation. The AEs were similar to those reported in the overall RADIANT-4 cohort 22 and was consistent with the known safety profile of everolimus. 21 In conclusion, although this is an exploratory subgroup analysis of a randomized phase III trial and the study was not powered for a comparison between subgroups, it represents the largest series of lung NET patients ever included in a phase III trial. These data indi- 
